The CMO Quality Management Gap

When Your CMO’s Quality System Looks Great on Paper (But Reality Hits Differently)

You’ve done everything right. You’ve vetted your Contract Manufacturing Organization, reviewed their quality management system documentation, confirmed their certifications, and signed the contract. Their QMS looks polished, comprehensive, and FDA-ready.

Then you get the first batch deviation report.

The manufacturing team missed a critical in-process check. The deviation investigation took three weeks longer than your timeline allows. The CAPA they proposed doesn’t actually address the root cause. And suddenly, you’re facing delays, additional costs, and uncomfortable conversations about whether this batch can even be released.

This is the moment when many biotech companies realize that managing CMO quality is one of the most underestimated challenges in bringing a product to market. You’re trusting another company—with their own priorities, processes, and pressures—to make your product with the quality your patients and the FDA expect.

The gap between a good-looking QMS and actual quality outcomes isn’t about the CMO’s capabilities. It’s about how you manage the relationship, define expectations, and integrate their manufacturing into your quality ecosystem.

Why CMO Quality Management Is So Underestimated

Most early-stage biotech companies approach CMO selection like they’re hiring a vendor. They evaluate capabilities, capacity, and cost. They review the CMO’s quality documentation and certifications. Everything checks out, so they move forward.

But here’s what gets missed: your CMO’s quality system was built for their products, their risk tolerance, and their regulatory history—not yours.

Their deviation thresholds might be looser than what you need. Their supplier qualification process might not cover the specific risks in your raw materials. Their batch record review might be thorough for their established products but miss nuances critical to your novel formulation.

This isn’t negligence. It’s misalignment. And it compounds because of three underlying issues:

1. Knowledge asymmetry - Your CMO knows manufacturing. You know your product and regulatory strategy. Neither fully understands the other’s constraints and priorities.

2. Misaligned incentives - Your CMO is balancing your product against their other clients, their operational efficiency, and their own risk management. A two-week delay to investigate a deviation properly might be acceptable to them but catastrophic to your clinical timeline.

3. Communication gaps - Manufacturing and quality speak different languages. When the CMO’s production team says “minor deviation,” and your quality team hears “potential batch failure,” you’re already in trouble.

The result? Issues that could have been prevented or quickly resolved become crises that threaten timelines, budgets, and regulatory standing.

The Four Mistakes That Derail CMO Quality

Over 13 years managing quality systems and CMO relationships, I’ve seen the same patterns derail even well-intentioned partnerships:

❌ Assuming the CMO’s QMS Covers Everything You Need

Your CMO has an FDA-compliant quality system. That’s table stakes. But compliance doesn’t equal alignment.

Their QMS defines how they’ll manufacture to regulatory standards. It doesn’t define what level of quality you require, which deviations are acceptable for your risk profile, or when you need to be involved in decisions.

What this looks like in practice: The CMO’s procedure allows 24-48 hours to document a deviation. Your clinical trial has a 12-hour reporting requirement to the IRB. Nobody discussed this upfront, so when a temperature excursion happens during manufacturing, you find out three days later—after you’ve already missed your reporting window.

The business impact: Protocol deviations, regulatory notifications, delayed batches, and erosion of trust with your clinical sites and regulatory agencies.

❌ Not Defining Clear Quality Agreements Upfront

Quality agreements are often treated as boilerplate contract appendices, drafted by legal teams focused on liability rather than operational clarity.

But a quality agreement should be your operational playbook. It should answer: Who owns what? Who decides what? Who gets notified when? What are the acceptance criteria? What triggers escalation?

What this looks like in practice: A deviation occurs. The CMO’s quality team investigates and proposes a CAPA. You disagree with their root cause analysis. Now you’re in a negotiation about who has final authority—while the batch sits in quarantine and your launch timeline slips.

The business impact: Contested decisions, delayed resolutions, relationship friction, and ultimately, deviations that don’t get properly addressed because the accountability was never clear.

❌ Treating Tech Transfer as a Manufacturing Problem, Not a Quality Problem

Tech transfer gets treated as a manufacturing milestone: Can they make the product at scale? But the quality implications are often an afterthought.

Manufacturing parameters that were “good enough” at lab scale create quality risks at commercial scale. Specifications that worked with your research-grade materials don’t account for variability in commercial-grade supplies. In-process controls that weren’t documented because “everyone just knew” become critical gaps when a new team takes over.

What this looks like in practice: During scale-up, the CMO discovers that a critical process parameter wasn’t adequately defined in the tech transfer package. They make adjustments based on their manufacturing experience—reasonable adjustments, even successful ones. But now you have a process that deviates from your original filing, requiring change controls, comparability studies, and potentially regulatory notifications.

The business impact: Months of additional validation work, regulatory complications, and the risk that your “transferred” process isn’t actually equivalent to what you studied in earlier phases.

❌ Waiting for Issues to Escalate Before Intervening

Many companies take a hands-off approach to CMO oversight: “They’re the manufacturing experts. We’ll step in if there’s a problem.”

By the time issues escalate to your attention, you’re in reactive mode. The deviation has already occurred. The investigation is already underway (possibly in the wrong direction). The timeline impact is already locked in.

What this looks like in practice: Your quarterly business review reveals that you’ve had 15 deviations over the past three months—a pattern you would have caught and addressed after deviation three if you’d been conducting regular quality reviews. Now you’re facing a trend that might trigger regulatory scrutiny and require a comprehensive corrective action plan.

The business impact: Preventable quality issues, compounding delays, higher costs, and regulatory risk that could have been avoided with earlier intervention.

What Actually Works: A Strategic Quality Partnership Framework

The most successful CMO relationships I’ve managed didn’t feel like vendor relationships. They felt like extensions of our internal team—with clear expectations, open communication, and shared accountability.

Here’s the framework that makes that possible:

✓ Quality Agreements Written BEFORE the Contract Is Signed

The quality agreement shouldn’t be an afterthought to the commercial contract. It should drive it.

Draft your quality agreement during vendor selection and negotiation. Use it to surface alignment issues early: Do they have the systems to meet your reporting timelines? Can they accommodate your deviation approval process? Will they commit to your batch release criteria?

What to include:

• Specific roles and responsibilities (not just “CMO is responsible for manufacturing quality”)

• Decision authority for deviations, CAPAs, and changes

• Notification timelines and escalation paths

• Batch release criteria and approval process

• Audit rights and frequency

• Key performance indicators for quality metrics

If you can’t agree on these terms before signing the contract, you’ll struggle with them throughout the relationship—except now you’re locked in.

✓ Regular Quality Reviews (Not Just Production Meetings)

Production meetings focus on timelines, capacity, and logistics. Quality reviews focus on trends, risks, and system performance.

Establish a regular cadence (monthly for active manufacturing, quarterly minimum otherwise) specifically for quality discussions:

• Deviation trends and root cause patterns

• CAPA effectiveness and closure status

• Change control pipeline and impact assessment

• Supplier quality and raw material variability

• Audit findings and corrective action progress

• Quality metrics and performance against targets

These reviews create visibility before issues become crises and build the relationship muscle memory for collaborative problem-solving.

✓ Clear Escalation Paths for Deviations and CAPAs

Define ahead of time what triggers your involvement and at what level.

Level 1:CMO handles within their standard process (e.g., minor documentation errors with no product impact)

Level 2:CMO investigates and proposes resolution, client quality reviews and approves (e.g., deviations with potential product impact)

Level 3: Joint investigation and resolution (e.g., deviations affecting critical quality attributes or regulatory commitments)

Level 4: Immediate escalation to senior leadership (e.g., product safety concerns, regulatory reportable events)

This framework prevents both extremes: micromanaging minor issues and being blindsided by major ones.

✓ Your Own Subject Matter Expert Who Can Speak Their Language

You need someone on your team—whether internal, consultant, or fractional resource—who understands both quality systems and manufacturing operations.

This person serves as the bridge between your strategic requirements and the CMO’s operational realities. They can:

• Translate your risk tolerance into specific quality requirements

• Review the CMO’s investigations and CAPAs with technical credibility

• Identify potential issues during tech transfer before they become deviations

• Navigate conversations when there are disagreements about root cause or acceptable risk

• Build peer relationships with the CMO’s quality team based on mutual respect

You don’t need to be their auditor. You need to be their strategic quality partner. An auditor shows up periodically to check compliance. A strategic partner is embedded in the ongoing relationship, collaborating to prevent issues and solve them quickly when they arise.

What This Looks Like in Practice

Let me give you an example of how this framework prevents the kinds of problems I described earlier.

A client was transferring a sterile fill-finish process to a CMO. During the quality agreement negotiation, we identified that the CMO’s standard environmental monitoring frequency was weekly, but our product’s risk assessment required daily monitoring during critical phases.

In the quality agreement, we specified:

• Daily environmental monitoring during active filling campaigns

• Real-time notification of any excursions (not the standard 48-hour documentation timeline)

• Joint review of any trending environmental results before they became excursions

• My client’s quality team had approval authority for any investigation or CAPA related to environmental control

Three months into manufacturing, the CMO’s environmental monitoring showed an upward trend in one classified area—still within limits, but trending in the wrong direction.

Because we had established regular quality reviews, we caught this in our monthly call. Because we had clear escalation paths, the CMO knew to flag it even though it wasn’t officially a deviation. Because we had a collaborative relationship, we jointly investigated and identified that a facilities modification in an adjacent area had changed the air pressure dynamics.

We implemented corrective action before it became a limit excursion, before it impacted a batch, and before it became a regulatory issue. Total timeline impact: zero. Total cost impact: minimal. Total relationship impact: strengthened, because both teams saw the partnership working as designed.

That’s what strategic quality partnership looks like.

The Bottom Line

If you’re outsourcing manufacturing, you’re not outsourcing quality. You’re extending your quality system to include a partner organization—and that partnership requires intentional design, active management, and ongoing investment.

The companies that treat CMO quality as a strategic priority from day one avoid the expensive, timeline-crushing surprises that derail those who treat it as a vendor management checkbox.

Your CMO’s quality system might look great on paper. The question is: have you built the partnership that ensures it works great in practice?

Need help establishing strategic quality partnerships with your CMOs—or building the quality systems that make outsourcing successful? Foundry Quality Group specializes in helping early-stage life sciences companies bridge the gap between research and commercial manufacturing. Let’s talk about your specific challenges.